Early Rash Development May Signal Superior Benefit With Lapatinib

Early development of rash identified patients with HER2-positive early breast cancer who received superior benefit from lapatinib-based therapy.

PDF) An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer

A retrospective, multicenter study of the efficacy of lapatinib

Forest plot of the adverse events for lapatinib and trastuzumab: (A)

Cutaneous responses in HER2+ metastatic breast cancer: A retrospective case series of a Phase 1b study of Tucatinib, an Oral HER2-specific inhibitor in combination with Capecitabine and/or Trastuzumab in third-line or later

Lapatinib: An Oral Dual Tyrosine Kinase Inhibitor for HER-2-Positive Breast Cancer

Number of days from start of lapatinib to onset of rash*

Lapatinib

Frontiers Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis

Time-dependent analysis for Rash, DFS, and OS*

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer - ScienceDirect

The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer - ScienceDirect

Cancers, Free Full-Text

Frontiers Lapatinib Plus Local Radiation Therapy for Brain

Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect

Tykerb: Package Insert / Prescribing Information